Bar Of Patent Suit Deductions Favors Drug Brands, Mylan Says
Barring Mylan from deducting $50 million in legal costs from patent infringement litigation would tilt the tax code in favor of brand-name drugmakers to the detriment of Mylan and other generic manufacturers,...To view the full article, register now.
Already a subscriber? Click here to view full article